With expansion a prime focus for businesses
worldwide, many are looking
The latest business developments from across Asia by Heather Hobbs To appear in our next issue, send your Business and Financial News stories to
heather@intlabmate.com
towards rapidly establishing new regions of growth, particularly in Europe and the Middle East.
ProCan Project to Advance Proteome Studies at CMRI Research will be carried out on a suite of Sciex TripleTOF® systems
using a tissue-based method developed at Ruedi Aebersold’s lab at the ETH, Zurich* which will profi le thousands of tumour samples per year, to identify and develop markers of disease risk, diagnosis, response to therapy, and prognosis on an industrial scale, while developing standard operating procedures for other facilities worldwide. Exclusive collaborators include Pressure Biosciences (PBIO) and Beckman Coulter, using pressure cycling technology and liquid handling workstations for increased sample preparation, throughput, and reproducibility.
From left to right: Professor Phil Robinson (Head of Cell Signaling Unit and co- developer of ProCan), Valentina Valova (Manager of Biomedical Proteomics Facility and ProCan, CMRI), Professor Roger Reddel (Director of CMRI and Head of Cancer research Unit) and Dr Christie Hunter (Sciex Director of OMICs Applications).
The Children’s Medical Research Institute (CMRI), through an alliance with life science analytical technologies company Sciex has announced the opening of ProCanTM
, the Australian Cancer Research Foundation
International Centre for the Proteome of Human Cancer. Established with a $10 million grant from the Australian Cancer Research Foundation, the partnership will enable large-scale proteome studies helping to industrialise the process of analysing tissue samples and identifying cancer biomarkers. The opening of the Centre was marked by the ProCan Industrialised Proteomics Centre Symposium, highlights of which can be accessed in the Sciex online symposium portal.
“This collaboration with Sciex enables ProCan to advance our vision to scale-up the process of fi nding causes of cancers, which is essential for earlier diagnosis and the development of new and even personalised approaches,” said Professor Phil Robinson, Head of the Cell Signalling Unit at CMRI and co-developer of ProCan. “The opening of this centre isn’t just an exciting milestone for us and for Sciex, but it’s exciting for the advancement of precision medicine at-large, as the information generated by ProCan will ultimately be free for anyone to access, helping scientists all around the world with rapid diagnoses and treatment planning.”
Jean-Paul Mangeolle, President of Sciex states, “Many years of partnerships and work have helped bring ProCan to fruition. Working closely with world-renowned scientists and complementary cutting edge technologies is driving new innovations like never before, offering better solutions for accelerating cancer research. We at Sciex are thrilled to be a part of this effort.”
*published in Nature Medicine
42710pr@reply-direct.com
Shonin Approval for ProBeam System
Varian Medical Systems has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the ProBeam®
system for proton therapy in Japan. The system was also showcased at the Particle Therapy Co-Operative Group (PTCOG), 11-13 May, 2017 in Yokohama, Japan.
The system’s pencil beam scanning technology allows clinicians to deliver more precise doses inside the tumour thus reducing risk to nearby healthy tissue. When combined with cone beam computed tomography (CBCT), the ProBeam also enables advanced image- guided adaptive therapy during the course of treatment helping to make it the most precise form of proton therapy available.
Because the proton beams can be controlled so that they deposit their energy within the tumour site rather than passing all the way through the patient the treatment is particularly suitable for paediatric cancer cases as well as for adults.
“We are very pleased that the ProBeam system has now received Shonin approval,” said Moataz Karmalawy, General Manager of Varian’s Particle Therapy division. “This approval is an important step in the growing availability of proton therapy in Japan and around the world.”
42711pr@reply-direct.com
Business
Opportunities Asia
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172
